Targets › NOS3
4 programs from 4 companies in 4 trials: 2 Phase 2, 1 Phase 4, 1 Phase 1; Psychiatry, Genitourinary, Oncology; next expected readout Dec 2026.
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets..; FUNCTION: [Isoform eNOS13C]: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming…. (UniProt, P29474)
Open in Phaseline: the race on NOS3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The University of Texas at Arlington | L-Arginine Substrate for nitric oxide synthase; overcomes ADMA inhibition to restore NO production an | NOS1, NOS2, NOS3 | Phase 4 | Chronic Kidney Disease | Dec 2026 |
| The Methodist Hospital Research Institute | Tilarginine Nitric oxide synthase inhibitor | NOS1, NOS2, NOS3 | Phase 2 | HER2-negative Breast Cancer | Dec 2026 |
| German University in Cairo | L-Arginine Nitric oxide synthase substrate; enhances NO production to improve vascular function and c | NOS2, NOS3 | Phase 2 | Cognition Disorders in Old Age | – |
| Louis Messina | L-Arginine Substrate for nitric oxide synthase, increases nitric oxide production | NOS1, NOS2, NOS3 | Phase 1 | Claudication, Intermittent | Jul 2027 |
Cognition Disorders in Old Age (1) Chronic Kidney Disease (1) HER2-negative Breast Cancer (1) Claudication, Intermittent (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.